Deals this week: Eris Lifesciences, Sichuan Languang Development, Xiangxue Pharmaceutical, Navamedic

Eris Lifesciences has reached an agreement to purchase Strides Shasun’s Indian generics business for $76.73m.

Under the agreement, Eris will take over the marketing and distribution rights for more than 130 products across multiple therapeutic areas owned by the generics business.

The acquisition is expected to close on 30 November and will boost Eris’ central nervous system (CNS) and gastro-intestinal therapies.

Sichuan Languang Development is set to issue asset-backed notes to raise $209.6m, having received the same statutory approvals.

Based in China, Sichuan Languang is engaged in manufacturing and distribution of pharmaceuticals.

Guoxin Securities and China Minsheng Banking will serve as underwriters for the issue.

"Sichuan Languang Development is set to issue asset-backed notes to raise $209.6m, having received the same statutory approvals."

Xiangxue Pharmaceutical, a Chinese pharmaceutical firm, plans to raise $75.28m from qualified institutional investors by issuing corporate bonds due 2022.

The funds will be utilised to clear the company’s existing liability on corporate bonds services.

Navamedic and G. Pohl-Boskamp GmbH & Co KG have joined forces to roll out the latter’s nitroglycerin sublingual powder formulation GoNitro in Norway.

Headquartered in Norway, Navamedic is engaged in the marketing and distribution of pharmaceutical products.

GoNitro provides acuter relief of an attack or prophylaxis of angina pectoris.